日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules

发现并鉴定出一种新型高效 MDM2-p53 拮抗剂 Brigimadlin,该药适用于间歇给药方案

Andreas Gollner #, Dorothea Rudolph #, Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Peter Jung, Harald Weinstabl, Jürgen Ramharter, Rolf Grempler, Jens Quant, Jörg Rinnenthal, Alejandro Pérez Pitarch, Bojana Golubovic, Daniel Gerlach, Gerd Bader, Kristiane Wetzel, Sebastian Otto, Christian Mandl, 

Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype

高选择性粘着斑激酶抑制剂 BI 853520 在腺癌异种移植模型中的疗效与间充质肿瘤表型相关

Ulrich A Hirt, Irene C Waizenegger, Norbert Schweifer, Christian Haslinger, Daniel Gerlach, Jürgen Braunger, Ulrike Weyer-Czernilofsky, Heinz Stadtmüller, Ioannis Sapountzis, Gerd Bader, Andreas Zoephel, Bojan Bister, Anke Baum, Jens Quant, Norbert Kraut, Pilar Garin-Chesa, Günther R Adolf

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

BIBF 1120:具有持续受体阻断作用和良好抗肿瘤功效的三重血管激酶抑制剂

Frank Hilberg, Gerald J Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin-Chesa, Gerd Bader, Andreas Zoephel, Jens Quant, Armin Heckel, Wolfgang J Rettig